Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study

Journal of Thoracic Oncology

Volumn 1, Issue 8, 2006, Pages 847-855

  Chang, Alex ^a   Parikh, Purvish ^b   Thongprasert, Sumitra ^c   Tan, Eng Huat ^d   Perng, Reury Perng ^e   Ganzon, Domingo ^f   Yang, Chih Hsin ^g   Tsao, Chao Jung ^h   Watkins, Claire ⁱ   Botwood, Nick ⁱ   Thatcher, Nick ^j  

^a Johns Hopkins Singapore   (Singapore)

^b TATA MEMORIAL HOSPITAL   (India)

^c Maharaj Nakorn Chiang Mai Hospital   (Thailand)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f Veterans Memorial Medical Center   (Philippines)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ ASTRAZENECA   (United Kingdom)

^j CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

Asian; EGFR TKI; Gefitinib; IRESSA; NSCLC

Indexed keywords

GEFITINIB; PLACEBO; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIAN; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EXFOLIATIVE DERMATITIS; FEMALE; HAZARD ASSESSMENT; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUSTULE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG ANTAGONISM; ETHNOLOGY; LUNG TUMOR; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 34248385777     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200610000-00014     Document Type: Article

References (35)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase, No. 5, version 2.0. Lyon: IARC Press, 2004.
2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
3. Wakeling AE, Barker AJ, Davies DH, et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 1996;38:67-73.
4. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-2246.
5. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003;290:2149-2158.
6. Nishiwaki Y, Yano S, Tamura T, et al. Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib. Gan To Kagaku Ryoho 2004;31:567-573.
7. Guan Z, Zhang L, Li L, et al. A Chinese, multicenter, phase II trial of gefitinib (IRESSA) in patients with non-small-cell lung cancer who had failed previous chemotherapy. Poster 2264 presented at the 11th WCLC, Barcelona, Spain, July 3-6, 2005.
8. Li W, Li L, Li J, et al. Iressa for the non-small lung cancer patients who failed prior chemotherapy and radiotherapy. Chin J Lung Cancer 2004;7:321-324.
9. Park J, Park B-B, Park S-H, et al. Geftinib ('Iressa', ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer. Poster presented at the WCLC, Vancouver, Canada, August 10-14, 2003. Lung Cancer 2003;41(Suppl 2):S249, abs P-620.
10. Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-4388.
11. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patient with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:1-9.
12. Wu YL, Yang X, Yang J-J, et al. ZD1839 for the treatment of heavily pretreated non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 2004;23:698, abs 7341.
13. Zhang X-T, Li L. Evaluation of safety and efficacy of ZD1839 as monotherapy for Chinese patients with advanced non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 2004;23:636, abs 7093.
14. Thatcher N, Chang A, Parikh P, et al. Gefitinib (IRESSA) plus best supportive care in pretreated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (ISEL). Lancet 2005;366:1527-1537.
15. The World Medical Association. The Declaration of Helsinki. Available at http://www.wma.net/e/policy/b3_e.html. Accessed July 26, 2006.
16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
18. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002;55:285-295.
19. National Cancer Institute. Cancer Therapy Evaluation Program. Common Toxicity Criteria manual. Common Toxicity Criteria, Version 2.0. Available at http://ctep.cancer.gov/forms/CTCManual_v4_10-4-99.pdf. Accessed March 24, 2005.
20. Northrop Grumman Corporation. Medical Dictionary for Regulatory Activities, Version 7.0. Reston, VA: Northrop Grumman, 2004.
21. Park JO, Lee SI, Song SY, et al. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003;33:533-537.
22. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
23. Ho C, Murray N, Laskin J, et al. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 2005;49:225-231.
24. Shepherd FA, Pereira JR, Ciuleanu E, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
25. Lee DH, Han JY, Lee HG, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005;11:3032-3037.
26. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-8092.
27. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
28. Lynch TJ, Bell D, Sordella R, et al. EGFR activating mutations underlying the responsiveness of NSCLC to gefitinib. Presentation during the "EGFR Mutations Predict Response to Gefitinib-Now What?" session at ASCO, New Orleans, LA, June 5- 8, 2004. Available at http://www.asco.org/ac/1,1003,_12- 002511-00_18-0026-00_19-0011621-00_21-008,00.asp. Accessed December 3, 2004.
29. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
30. Rosell R, Ichinose Y, Taron M, et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 2005;50:25-33.
31. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167.
32. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy. Eur J Cancer 2005;42:17-23.
33. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
34. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA™) monotherapy. Clinical experience in non-small-cell lung cancer. Drug Saf 2004;27:1081-1092.
35. Yoshida S. The results of gefitinib prospective investigation. Med Drug J 2005;41:772-789.